Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,100.3
39.0 (1.27%)

 

  • STI Straits Times Index
    3,100.3
    39.0 (1.27%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,533.0
    1.0 (0.06%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,208.8
    16.6 (0.07%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,582.8
    -30.2 (-0.84%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    30,240.1
    -8.8 (-0.03%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,122.5
    -22.3 (-0.36%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 961.3M
  • Value: 1,209.1M
  • Rise: 179
  • Fall: 150
  • Unch: 426

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Hatten Land0.055-0.003
Sembcorp Marine0.081-
YZJ Shipbldg SGD1.400-0.030
CapitaLandInvest3.530+0.230
Jiutian Chemical0.079+0.001
Singtel2.510+0.010
Intl Cement0.032+0.001
GSS Energy0.074+0.002
Genting Sing0.745+0.005
CapLand IntCom T2.090+0.010

World Indices

World Indices
Name Last Change
Nasdaq 15,047.7 -4.5
HSI 24,208.8 +16.6
HSCEI 8,583.8 -21.2
Jakarta 6,122.5 -22.3
Nikkei 225 30,240.1 -8.8
SSE Comp 3,582.8 -30.2
Shanghai A 3,755.1 -31.7
Shanghai B 271.1 -3.6
KOSPI 3,133.6 +8.4

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

IX Biopharma IX BIOPHARMA LTD.
Quotes 10 Minutes Delayed. Updated at 27 Sep 2021 17:00
Last (SGD): 0.230 Change: - High: 0.230 Remarks: -
Change (%): - Low: 0.225
Open 0.230 Yesterday's Close 0.230
Buy Price 0.225 Sell Price 0.230
Buy Volume ('000) 1,120.9 Sell Volume ('000) 269.9
Cumulative Volume ('000) 231.4 Cumulative Value 53,172
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a -0.01104 Trailing EPS (SGD) e -0.01104 NAV (SGD) b 0.0288
PE a - Trailing PE f - Price / NAV b 7.9861
Dividend (SGD) d - Cash In Hand (SGD) g 0.0075 Issued & Paid-up Shares c 746,168,000
Dividend Yield (%) d - Price / Cash In Hand g 30.667 Treasury Shares h -
Beta - 75 Daysi 0.230 R-Squared - 75 Days(%)i 0.78 Market Cap (M) 171.619
Beta - 500 Daysi 0.483 R-Squared - 500 Days (%)i 1.28 Enterprise Value (M) 169.649
Piotroski F Score 2 Exchange Code 42C Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 33.5152 6-Month VWAP 0.240 Free Float (%) 53.9
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Prof, Scientific & Technical Activities - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Index Components FTSE ST Catalist Index
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 28 Jul 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference IX Biopharma SGX 171.619 - - 7.9861 -
Industry Medical & Biotechnology SGX 1,017.878 18.819 16.069 1.4334 2.993
Pharmaceuticals: Major SGX 89.416 2431.015 115.115 3.6758 0.694
Index FTSE ST Catalist Index SGX 61.063 30.299 22.705 1.3702 1.908
Local Peer Hyphens Pharma SGX 93.133 15.115 15.031 1.8776 2.000
Local Peer Pharmesis Intl SGX 3.496 - - 0.2999 -
Global Peer JOHNSON & JOHNSON NYSE 432,674.413 29.406 24.353 6.2184 2.422
Global Peer PFIZER INC NYSE 246,357.959 25.620 18.624 3.5173 3.457
Global Peer ELI LILLY AND COMPANY NYSE 221,620.686 35.782 36.507 34.3897 1.278
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 201,886.451 24.862 22.446 3.7357 2.324
Global Peer ABBVIE INC NYSE 189,211.963 41.530 28.716 15.0538 4.515
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 186,979.991 58.504 49.584 11.9278 1.924
Global Peer MERCK & CO INC NYSE 186,334.146 26.367 33.447 5.5966 3.368
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 178,496.792 27.700 25.073 17.0727 1.336
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 133,837.685 - - 3.6361 3.085
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 121,141.024 8.630 17.493 1.6154 2.790
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), REPLIGEN CORP (NASDAQ), VIATRIS INC (NASDAQ), HANSOH PHARMA (HKEx), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), CUREVAC NV (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), ORGANON & CO (NYSE), SINOPHARM (HKEx), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), REMEGEN-B (HKEx), HUTCHMED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), ALLAKOS INC (NASDAQ), SH PHARMA (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), JUNSHI BIO (HKEx), HYGEIA HEALTH (HKEx), AKESO-B (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), CMS (HKEx), BAIYUNSHAN PH (HKEx), IMMUNITYBIO INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), INNOCARE-B (HKEx), CARSGEN-B (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CHINARES PHARMA (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), CHINAGRANDPHARM (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), SIMCERE PHARMA (HKEx), ERASCA INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), TRAD CHI MED (HKEx), ADC THERAPEUTICS SA (NYSE), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), EVEREST MED-B (HKEx), QUANTERIX CORPORATION (NASDAQ), HENLIUS (HKEx), CSTONE PHARMA-B (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), SSY GROUP (HKEx), HEPALINK (HKEx), OCUMENSION-B (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), KRONOS BIO INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), ZYMEWORKS INC (NYSE), Y-MABS THERAPEUTICS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), UNITED LAB (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), ICOSAVAX INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), FULCRUM THERAPEUTICS INC (NASDAQ), TONGRENTANGCM (HKEx), FORMA THERAPEUTICS HLDGS INC (NASDAQ), IMMUNOTECH-B (HKEx), REPARE THERAPEUTICS INC (NASDAQ), GH RESEARCH PLC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), Kimia Farma Tbk. (IDX), ORIC PHARMACEUTICALS INC (NASDAQ), SCICLONE PHARMA (HKEx), GOSSAMER BIO INC (NASDAQ), CKLIFE SCIENCES (HKEx), PRAXIS PRECISION MEDICINES INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), ANTENGENE-B (HKEx), MIND MEDICINE (MINDMED) INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ANNEXON INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), VERU INC (NASDAQ), PETIQ INC (NASDAQ), SHINEWAY PHARM (HKEx), ALIGOS THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), PHARVARIS NV (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), HUA MEDICINE-B (HKEx), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), ZHAOKE OPHTH-B (HKEx), SIGA TECHNOLOGIES INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), AC IMMUNE SA (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), CLENE INC (NASDAQ), EVOLUS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), IGBB (Bursa), 89BIO INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), RACE ONCOLOGY LTD (ASX), SILVERBACK THERAPEUTICS INC (NASDAQ), CYBIN INC (NYSE American), NEXIMMUNE INC (NASDAQ), ESSA PHARMA INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), ATHENEX INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), TOT BIOPHARM-B (HKEx), PYC THERAPEUTICS LIMITED (ASX), OYSTER POINT PHARMA INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), DURECT CORP (NASDAQ), INOZYME PHARMA INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), DAWNRAYS PHARMA (HKEx), AFT PHARMACEUTICALS LTD (ASX), IMPEL NEUROPHARMA INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), ANNOVIS BIO INC (NYSE American), CHECKPOINT THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), BSTEAD (Bursa), OBSEVA SA (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), VINCERX PHARMA INC (NASDAQ), HARROW HEALTH INC (NASDAQ), PHARMA (Bursa), MUSTANG BIO INC (NASDAQ), IMMUNIC INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), FUSEN PHARM (HKEx), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), TRICIDA INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), IP (SET), KALA PHARMACEUTICALS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), CH BIOTECH SER (HKEx), XERIS PHARMACEUTICALS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), NOVAN INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), POLYPID LTD (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), ENTERA BIO LTD (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), GENPREX INC (NASDAQ), LANNETT CO INC (NYSE), NEUBASE THERAPEUTICS INC (NASDAQ), ZHONGZHIPHARM (HKEx), EYENOVIA INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), NOXOPHARM LTD (ASX), ODONATE THERAPEUTICS INC (NASDAQ), IMARA INC (NASDAQ), Merck Tbk. (IDX), YUMANITY THERAPEUTICS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), GALECTO INC (NASDAQ), CHARMACY PHAR (HKEx), APREA THERAPEUTICS INC (NASDAQ), KOTRA (Bursa), CRESO PHARMA LTD (ASX), ELEDON PHARMACEUTICALS INC (NASDAQ), MEDIWOUND LTD (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), NEW RAY MEDIC (HKEx), OCUPHIRE PHARMA INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), GRAYBUG VISION INC (NASDAQ), PROPHASE LABS INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), SANAI HEALTH GP (HKEx), ALLENA PHARMACEUTICALS INC (NASDAQ), Phapros Tbk. (IDX), NC HEALTHCARE (HKEx), PAK FAH YEOW (HKEx), MANNATECH INC (NASDAQ), EXOPHARM LTD (ASX), NOVA (Bursa), BIOHLDG (Bursa), BRICKELL BIOTECH INC (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), RENOVORX INC (NASDAQ), MODERN CHI MED (HKEx), INVION LTD (ASX), SYNAPTOGENIX INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), NEP INTERLONG (HKEx), BAUDAX BIO INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), UNIVERSE PHARMACEUTICALS INC (NASDAQ), WAI YUEN TONG (HKEx), SEQLL INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), DERMATA THERAPEUTICS INC (NASDAQ), PHARMAXIS (ASX), ASSERTIO HOLDINGS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), PURAPHARM (HKEx), PASITHEA THERAPEUTICS CORP (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), AGEX THERAPEUTICS INC (NYSE American), ACER THERAPEUTICS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), JCT (SET), SUNZEN (Bursa), EXTRAWELL PHAR (HKEx), TREVI THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), NLS PHARMACEUTICS LTD (NASDAQ), PALLA PHARMA LTD (ASX), PANBELA THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), AVENUE THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ACRUX (ASX), IMMURON LIMITED (ASX), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), SINOLIFE UTD (HKEx), CHINA SXT PHARMACEUTICALS INC (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.005
+2.22 %
10 Days --0.005
-2.13 %
20 Days -+0.005
+2.22 %
Medium Term Return 3 Months --0.012
-4.96 %
6 Months -+0.008
+3.60 %
1 Year --0.002
-0.86 %
Long Term Return 2 Years -+0.013
+5.99 %
3 Years -+0.057
+32.95 %
5 Years --0.081
-26.05 %
Annualised Return Annualised --
-5.86 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.207 - 0.286 Change From 1 Year Low +0.022 % Change From 1 Year Low (%) +10.84
Change From 1 Year High -0.057 % Change From 1 Year High (%) -19.72
2 Years Range 0.128 - 0.346 Change From 2 Years Low +0.102 % Change From 2 Years Low (%) +79.13
Change From 2 Years High -0.116 % Change From 2 Years High (%) -33.49
5 Years Range 0.128 - 0.375 Change From 5 Years Low +0.102 % Change From 5 Years Low (%) +79.13
Change From 5 Years High -0.145 % Change From 5 Years High (%) -38.73
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery. iX Biopharma’s pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma’s drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world’s first freeze-dried sublingual medicinal cannabis wafer. The Group’s nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products in Australia through more than 250 pharmacies and health food shops, in China through its flagship stores on Tmall Global and JD Worldwide, and globally through its online store.

IPO Performance

Listing Date 22 Jul 2015 Full Subscription Rate (x) 1.36
No of Placement Shares (M) 64.50 No of Public Offer Shares (M) 1.00 Public Offer Subscription Rate (x) 24.65
IPO Price (SGD) a 0.449 First Day Close (SGD) a 0.545 First Week Close (SGD) a 0.409
Current vs IPO Price (%) -48.78 First Day Gain (%) +21.38 First Week Gain (%) -8.91
Notes:
  1. Adjusted for the following: Rights Issue 1 for 25 @ $0.21 on 22/06/2016, Rights Issue 7 for 100 @ S$0.20 on 29/06/2021

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2020 Jun 2020 Part 1(4.14 MB)
Annual Report 2019 Jun 2019 Part 1(4.31 MB)
Annual Report 2018 Jun 2018 Part 1(6.28 MB)
Annual Report 2017 Jun 2017 Part 1(1.40 MB)
Annual Report 2016 Jun 2016 Part 1(4.32 MB)
Part 2(0.12 MB)
Annual Report 2015 Jun 2015 Part 1(0.59 MB)
IPO Prospectus
IPO Prospectus 2015 Jul 2015 Part 1(3.65 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
27 Sep 2021 0.230 0.230 0.225 0.230 231,400 0.2298
24 Sep 2021 0.230 0.240 0.230 0.230 676,000 0.2336
23 Sep 2021 0.230 0.230 0.225 0.230 942,100 0.2298
22 Sep 2021 0.230 0.230 0.230 0.230 212,300 0.2300
21 Sep 2021 0.230 0.235 0.225 0.235 651,900 0.2296
20 Sep 2021 0.225 0.230 0.225 0.225 209,900 0.2267
17 Sep 2021 0.225 0.230 0.225 0.225 104,000 0.2300
16 Sep 2021 0.225 0.230 0.225 0.225 110,600 0.2299
15 Sep 2021 0.230 0.230 0.225 0.225 432,800 0.2299
14 Sep 2021 0.235 0.235 0.230 0.230 964,800 0.2305
13 Sep 2021 0.230 0.235 0.230 0.235 603,300 0.2349
10 Sep 2021 0.230 0.230 0.230 0.230 121,400 0.2300
09 Sep 2021 0.230 0.235 0.230 0.230 478,700 0.2305
08 Sep 2021 0.225 0.235 0.225 0.230 81,700 0.2302
07 Sep 2021 0.225 0.235 0.225 0.230 655,900 0.2296
06 Sep 2021 0.230 0.230 0.225 0.225 610,500 0.2300
03 Sep 2021 0.235 0.235 0.225 0.230 318,700 0.2301
02 Sep 2021 0.230 0.235 0.230 0.230 239,400 0.2317
01 Sep 2021 0.225 0.230 0.225 0.230 482,400 0.2266
31 Aug 2021 0.230 0.230 0.225 0.225 169,300 0.2294
30 Aug 2021 0.230 0.230 0.225 0.225 620,300 0.2280
27 Aug 2021 0.230 0.230 0.225 0.225 30,000 0.2251
Summary
Current 2 Weeks
(14 Sep 2021 to 27 Sep 2021)
0.235 0.240 0.225 0.230 4,535,800 -
Previous 2 Weeks
(31 Aug 2021 to 13 Sep 2021)
0.230 0.240 0.225 0.235 3,761,300 -
4 Weeks from
(02 Aug 2021 to 30 Aug 2021)
0.230 0.240 0.225 0.225 20,147,900 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.